microdosing glp-1 agonists vs. Standard Dosing: A Provider-Guided Comparison Benefits of GLP-1 Microdosing GLP-1
Description
David Kessler says the new weight-loss drugs are a powerful tool to fight obesity
The advent of incretin mimetics such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has enriched the armamentarium for diabetes management owing to their glycaemic as well as extra-glycaemic benefits
Please use caution if you have allergies or sensitivities to any of the listed ingredients
Larger randomized controlled trials with long-term follow-up are necessary to confirm these associations and evaluate the risk-benefit ratios
These findings align with prior randomized trials and meta-analyses suggesting class-level cardiovascular benefit
Why low and slow is the way to go.
